These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 23511300)

  • 21. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emergence of vancomycin-intermediate and -resistant Staphylococcus aureus among methicillin-resistant S. aureus isolated from clinical specimens in the northwest of Iran.
    Ghahremani M; Jazani NH; Sharifi Y
    J Glob Antimicrob Resist; 2018 Sep; 14():4-9. PubMed ID: 29454049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter?
    Claeys KC; Lagnf AM; Hallesy JA; Compton MT; Gravelin AL; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1708-16. PubMed ID: 26729497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials.
    Hos NJ; Jazmati N; Stefanik D; Hellmich M; AlSael H; Kern WV; Rieg S; Wisplinghoff H; Seifert H; Kaasch AJ
    J Infect; 2017 Mar; 74(3):248-259. PubMed ID: 28017826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
    Lodise TP; Drusano GL; Zasowski E; Dihmess A; Lazariu V; Cosler L; McNutt LA
    Clin Infect Dis; 2014 Sep; 59(5):666-75. PubMed ID: 24867791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.
    Frymoyer A; Hersh AL; Benet LZ; Guglielmo BJ
    Pediatr Infect Dis J; 2009 May; 28(5):398-402. PubMed ID: 19295465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
    Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
    Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans.
    Fink SL; Martinello RA; Campbell SM; Murray TS
    Antimicrob Agents Chemother; 2012 Jan; 56(1):582-3. PubMed ID: 22064529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?
    Patel K; Crumby AS; Maples HD
    Paediatr Drugs; 2015 Apr; 17(2):97-103. PubMed ID: 25644329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
    Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
    J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching Hospital.
    da Costa TM; Morgado PG; Cavalcante FS; Damasco AP; Nouér SA; Dos Santos KR
    PLoS One; 2016; 11(8):e0160506. PubMed ID: 27575698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation.
    Khatib R; Riederer K; Sharma M; Shemes S; Iyer SP; Szpunar S
    J Clin Microbiol; 2015 Nov; 53(11):3543-6. PubMed ID: 26311860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
    Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia.
    Wi YM; Kim JM; Joo EJ; Ha YE; Kang CI; Ko KS; Chung DR; Song JH; Peck KR
    Int J Antimicrob Agents; 2012 Aug; 40(2):108-13. PubMed ID: 22633565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates.
    Pitz AM; Yu F; Hermsen ED; Rupp ME; Fey PD; Olsen KM
    J Clin Microbiol; 2011 Jan; 49(1):269-74. PubMed ID: 20962147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
    Capone A; Cafiso V; Campanile F; Parisi G; Mariani B; Petrosillo N; Stefani S
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs.
    Arun A; Swamy S; Jacob K; Sharma R; Kohlhoff SA; Hammerschlag MR
    Minerva Pediatr; 2018 Jun; 70(3):207-211. PubMed ID: 28006894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
    Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
    Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The change and significance of vancomycin minimal inhibitory concentration against methicillin-resistant Staphylococcus aureus isolates from inpatients with lower respiratory tract infection].
    Yang W; He B; Ning YZ; Li Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Apr; 36(4):288-92. PubMed ID: 23945344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia.
    Takesue Y; Nakajima K; Takahashi Y; Ichiki K; Ishihara M; Wada Y; Tsuchida T; Uchino M; Ikeuchi H
    J Infect Chemother; 2011 Feb; 17(1):52-7. PubMed ID: 20625789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.